A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping
- 16 January 2018
- journal article
- research article
- Published by Springer Nature in Journal of Human Genetics
- Vol. 63 (3) , 365-375
Abstract
Oligonucleotide-mediated splicing modulation is a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Recently, eteplirsen, a phosphorodiamidate morpholino oligomer-based splice-switching oligonucleotide (SSO) targeting DMD exon 51, was approved by the U.S. Food and Drug Administration as the first antisense-based drug for DMD patients. For further exploring SSOs targeting other exons in the DMD gene, the efficacy of exon skipping and protein rescue with each SSO sequence needs evaluations in vitro. However, only a few immortalized muscle cell lines derived from DMD patients have been reported and are available to test the efficacy of exon skipping in vitro. To solve this problem, we generated a novel immortalized DMD muscle cell line from the human rhabdomyosarcoma (RD) cell line. We removed DMD exons 51–57 (~0.3 Mb) in the RD cell line using the CRISPR/Cas9 system. Additionally, in this DMD model cell line, we evaluated the exon 50 skipping activity of previously reported SSOs at both the mRNA and protein levels. CRISPR/Cas9-mediated gene editing of the DMD gene in the RD cell line will allow for assessment of SSOs targeting most of the rare mutations in the DMD gene.Keywords
This publication has 31 references indexed in Scilit:
- Nuclease‐mediated genome editing: At the front‐line of functional genomics technologyDevelopment, Growth & Differentiation, 2014
- Primer-BLAST: A tool to design target-specific primers for polymerase chain reactionBMC Bioinformatics, 2012
- Enhanced Exon-skipping Induced by U7 snRNA Carrying a Splicing Silencer Sequence: Promising Tool for DMD TherapyMolecular Therapy, 2009
- Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating MechanismsMolecular Therapy, 2009
- Sequential Recruitment of PCAF and BRG1 Contributes to Myogenin Activation in 12-O-Tetradecanoylphorbol-13-acetate-induced Early Differentiation of Rhabdomyosarcoma-derived CellsJournal of Biological Chemistry, 2007
- Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame ruleMuscle & Nerve, 2006
- Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.Proceedings of the National Academy of Sciences, 1993
- TPA-Induced Differentiation of Human Rhabdomyosarcoma Cells: Expression of the Myogenic Regulatory FactorsExperimental Cell Research, 1993
- The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscleNature, 1988
- The complete sequence of dystrophin predicts a rod-shaped cytoskeletal proteinCell, 1988